CBIO Catalyst Biosciences Inc.

8.7
-0.02  -0%
Previous Close 8.72
Open 8.7
Price To Book 0.87
Market Cap 104139365
Shares 11,970,042
Volume 131,907
Short Ratio
Av. Daily Volume 202,383

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 top-line data due 3Q 2019 and final data due 4Q 2019.
Marzeptacog alfa
Hemophilia
Phase 2b initiation announced April 2, 2019. Top-line data due 2H 2019.
Dalcinonacog alfa – DalcA
Hemophilia B

Latest News

  1. Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference
  2. Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B
  3. Could The Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ownership Structure Tell Us Something Useful?
  4. Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)
  5. Catalyst Biosciences Inc (CBIO) Files 10-K for the Fiscal Year Ended on December 31, 2018
  6. Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update
  7. Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
  8. New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives and Sustained Production
  9. Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
  10. Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
  11. Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
  12. Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
  13. Is Catalyst Biosciences, Inc.’s (NASDAQ:CBIO) Balance Sheet A Threat To Its Future?
  14. Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll
  15. These 5 Stocks Make Great Buys on New Analyst Coverage
  16. Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
  17. Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
  18. Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
  19. What Did Catalyst Biosciences Inc’s (NASDAQ:CBIO) CEO Take Home Last Year?
  20. Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition